Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
BM mesenchymal stromal cell–derived exosomes facilitate multiple myeloma progression
Aldo M. Roccaro, … , David T. Scadden, Irene M. Ghobrial
Aldo M. Roccaro, … , David T. Scadden, Irene M. Ghobrial
Published March 1, 2013
Citation Information: J Clin Invest. 2013;123(4):1542-1555. https://doi.org/10.1172/JCI66517.
View: Text | PDF | Erratum
Research Article Oncology

BM mesenchymal stromal cell–derived exosomes facilitate multiple myeloma progression

  • Text
  • PDF
Abstract

BM mesenchymal stromal cells (BM-MSCs) support multiple myeloma (MM) cell growth, but little is known about the putative mechanisms by which the BM microenvironment plays an oncogenic role in this disease. Cell-cell communication is mediated by exosomes. In this study, we showed that MM BM-MSCs release exosomes that are transferred to MM cells, thereby resulting in modulation of tumor growth in vivo. Exosomal microRNA (miR) content differed between MM and normal BM-MSCs, with a lower content of the tumor suppressor miR-15a. In addition, MM BM-MSC–derived exosomes had higher levels of oncogenic proteins, cytokines, and adhesion molecules compared with exosomes from the cells of origin. Importantly, whereas MM BM-MSC–derived exosomes promoted MM tumor growth, normal BM-MSC exosomes inhibited the growth of MM cells. In summary, these in vitro and in vivo studies demonstrated that exosome transfer from BM-MSCs to clonal plasma cells represents a previously undescribed and unique mechanism that highlights the contribution of BM-MSCs to MM disease progression.

Authors

Aldo M. Roccaro, Antonio Sacco, Patricia Maiso, Abdel Kareem Azab, Yu-Tzu Tai, Michaela Reagan, Feda Azab, Ludmila M. Flores, Federico Campigotto, Edie Weller, Kenneth C. Anderson, David T. Scadden, Irene M. Ghobrial

×

Figure 6

miR-15a expression differs between normal and MM BM-MSCs, and miR-15a–containing exosomes are transferred into MM cells.

Options: View larger image (or click on image) Download as PowerPoint

miR-15a expression differs between normal and MM BM-MSCs, and miR-15a–c...
(A) miR expression profiling on total RNA isolated from normal (n = 4), MM (n = 7), and MGUS (n = 2) BM-MSC–derived exosomes. A heatmap was generated after supervised hierarchical cluster analysis. Differential miR expression is shown by red (upregulation) versus blue (downregulation) intensity (d-Chip software; normal versus MM, 1.5-fold change, P < 0.05). (B) MM.1S and RPMI.8226 MM cells were cultured in the absence or presence of primary MM (n = 4) or normal (n = 3) BM-MSCs or the HS-5 cell line for 48 hours. miR-15a expression was determined by qRT-PCR in MM cells (2–ΔΔCt method, normalized to RNU6BmiR as reference). Results are average ± SD of 3 independent experiments. miR-15a was upregulated in MM cells when in contact with normal BM-MSCs. (C) Murine exosomes were isolated from BM of WT or miR-15a/16-1–/– mice and subsequently added to MM cells for 48 hours. miR-15a levels were determined by qRT-PCR in human MM cells (2–ΔΔCt method, normalized to C. elegansmiR-39 reference, used as spiked control). Bars represent SD. (D) MM cells were cultured in the presence or absence of murine WT or miR-15a/16-1–/– BM-MSCs for 48 hours, and cell proliferation was assessed as [3H]-thymidine uptake. Bars indicate SD. (E and F) HS-5 cells (E) or primary BM-MSCs (F) were transfected with scramble, pre–miR-15a, or anti–miR-15a probe. Cells were then exposed to the indicated exosomes for 48 hours. Cell-conditioned media absent cells and processed as in all samples tested served as control. Cell proliferation was assessed using [3H]-thymidine uptake assay. Bars indicate SD.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts